Could a Two-Drug combo supercharge weight loss?

NCT ID NCT06373146

First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 25 times

Summary

This study tests whether adding a new drug (mibavademab) to an existing weight-loss medication (tirzepatide) leads to greater weight loss than tirzepatide alone. About 392 adults with obesity (BMI 30-40) will receive weekly injections for up to 74 weeks. The goal is to see if the combination is more effective for managing obesity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CTI Clinical Research Center

    Cincinnati, Ohio, 45212, United States

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • Hassman Research Institute Marlton Site

    Marlton, New Jersey, 08053, United States

  • Irvine Clinical Research

    Irvine, California, 92614, United States

  • Juno Research

    Houston, Texas, 77040, United States

  • Lillestol Research

    Fargo, North Dakota, 58104, United States

  • Northwest Clinical Research Center

    Bellevue, Washington, 98007, United States

  • Solaris Clinical Research

    Meridian, Idaho, 83646, United States

  • South Texas Clinical Research

    Corpus Christi, Texas, 78404, United States

  • Tandem Clinical Research

    Marrero, Louisiana, 70072, United States

  • Velocity Clinical Research - New Orleans

    New Orleans, Louisiana, 70119, United States

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

  • Velocity Clinical Research, Gardena

    Gardena, California, 90247, United States

  • Velocity Clinical Research, Los Angeles

    Los Angeles, California, 90017, United States

  • Velocity Clinical Research, North Hollywood

    North Hollywood, California, 91606, United States

  • Velocity Clinical Research, Panorama City

    Van Nuys, California, 91405, United States

  • Velocity Clinical Research, Santa Ana

    Santa Ana, California, 92704, United States

Conditions

Explore the condition pages connected to this study.